Beijing, China – The 2022 Urology Laparoscopy and Robotics Conference was held in Beijing from September 2 to 4, during which Shanghai MicroPort MedBot (Group) Co., Ltd. (hereinafter referred to as “MicroPort^® MedBot^®”) made its debut with its self-developed laparoscopic and robotic solutions (DFVision® 3D Electronic Laparoscope and Toumai® Laparoscopic Surgical Robot). In order to meet the demand for more precise and efficient minimally invasive medical treatment, MicroPort^® MedBot^® pursues independent research and technological innovation unremittingly to take the lead in the fields of laparoscopy and robotics, committed to exploring the breakthroughs for the development of Chinese-developed high-end medical surgical equipment.

The annual Laparoscopy and Robotics Conference, chaired by academician Xu Zhang, Director of the Urology Department of the Chinese PLA General Hospital, originated from the Laparoscopy Training Course for Urology held in Tongji Hospital under Tongji Medical College of HUST in 2000 and was transformed to the Minimally Invasive Urology Course of the PLA General Hospital in Beijing on the occasion of the Olympic Games in 2008, and then to the current 2022 Beijing  Urology Laparoscopy and Robotics Conference has been successfully held for 22 sessions. Under the superior inheritance and unremitting insistence of academician Xu Zhang’s team for 22 years, the conference has been continuously pushed forward in its content and dissemination methods, gaining widespread support and attention from experts and scholars at home and abroad, thereby establishing itself as one of the high-end academic conferences with the great academic value that is now unanimously recognized by international and Chinese-developed urology scholars!

The conference brought together prestigious urological experts from home and abroad, adhering to the tenet of “exchange, innovation, integration, and development”, and upholding the concept of drawing upon others’ advantages to pursue a win-win growth. Via surgical demonstrations, new technologies, methods, and techniques of minimally invasive urological surgeries were manifested and discussed at the event. The Urology Department of the Chinese PLA General Hospital, the CUA Robotics Group, the Urology Branch of the Beijing Medical Association, and Chinese-developed urological masters, equipped with great passion, demonstrated classical and cutting-edge innovative procedures in urological laparoscopic and robotic surgeries in a comprehensive, multi-angle manner, fully showcasing the strong strength of the Urology Department of the PLA General Hospital in minimally invasive surgeries. The counterparts from all parts of the country feasted their eyes on a dazzling array of cutting-edge technology and excellent achievements by the juxtaposition of laparoscopic and robotic surgeries as well as classic surgeries and innovative procedures, with top experts sharing their insights to create an academic exchange platform for unimpeded communication and cooperation. The conference was held in the form of offline sessions and online live streaming, garnering nearly 300,000 views in its five live streaming channels.

The MicroPort^® MedBot^® booth made a stunning appearance with a giant LED screen, whose high-definition surgical images attracted many experts and leaders to stop by and take a closer look. Academician Xu Zhang, chairman of the conference, and related experts and leaders visited the booth by carefully observing the product demonstration, getting informed of the technical advantages, and experiencing the operational performance on their own. They heaped praise on Toumai^® and DFVision^® amid an animated atmosphere at the booth. Toumai^® and DFVision^® lent a sci-fi touch to this academic event with their top-notch technology advantagesand won the recognition of the experts on site thanks to their excellent operation performance during the test drive.

The experts said that as an innovator and leader of Chinese-developed surgical robots, MicroPort^® MedBot^® will enable technology and products embodying the “intelligent manufacturing in China” to be introduced in hospitals at a faster pace, thereby providing more learning and experience opportunities for clinicians to continuously benefit more patients.

In the conference “The Light of Chinese-developed Products – Chinese-developed Robot Demonstration Symposium”, Professor Jie Yang, an expert from Jiangsu Province Hospital to aid Xinjiang, delivered a speech entitled “Forging a Sharp Scalpel of Life and Times – Application of Chinese-developed Toumai^® Robot in Urology Surgery”, in which he introduced the application of Toumai^® in urology and Toumai^® 5G remote surgeries to the experts and leaders at the conference. According to Prof. Jie Yang, Toumai^® has completed 17 robot-assisted urological surgeries so far in Kizilsu Kirghiz People’s Hospital, specifically, 3 cases of 5G-based ultra-remote surgery across 5,000 km and 14 cases of bedside surgery, including a highly difficult robot-assisted single-port partial nephrectomy. The exquisite surgical skills of the expert team to aid Xinjiang, coupled with the stable performance of Toumai^®, have brought hope for life and led to improved quality of life for a large number of families in Kizilsu Kirghiz.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said, “As technology and society advance, medical robotic surgeries have become a mainstream development direction. The increasing demand of patients for robotic surgeries and the government’s support for Chinese-developed surgical robots have enabled robotic minimally invasive surgeries in China to grow rapidly. Looking ahead, MicroPort^® MedBot^® will continue to stay true to its original aspiration to “Make Surgery Easier, Safer and Less Invasive”, allow more of its leading medical technologies and products to reach more prefecture- and county-level hospitals, and offer more learning and experience opportunities to clinicians, thus creating more intelligent surgical solutions for clinical diagnosis and treatment while delivering constant benefits to patients.

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®, stock code: 02252.HK) is a sub-group of MicroPort Scientific Corporation (MicroPort^®, stock code: 00853.HK). It initiated the development of Toumai^® Laparoscopic Surgery Robot in 2014 as an internal incubation project of MicroPort^®, established the company in China in 2015 to start its corporate operation, and kickstarted the development of Honghu Orthopedic Surgical Robot. On November 2, 2021, MicroPort^® MedBot^® was successfully listed on the Main Board of HKEX, assuming the mission to reshape and prolong life through a robotic intelligent surgical total solution. This milestone event marks its new journey of medical technology innovation to shape the era of ultra-intelligent surgeries and its endeavor to fulfill the founding aspiration to “Make Surgery Easier, Safer and Less Invasive”.